Keros Therapeutics paid its 3 named executives $4.8M in total in FY2025 (Dec). CEO Jasbir Seehra, Ph.D. was paid $2.5M of that.
Pay$100 in the stock at the end of FY20 → $29
Pay of each named executive
Christopher RovaldiFormer President and Chief Operating Officer
| FY2024 (Dec) | |||||||
| FY2023 (Dec) | |||||||
| FY2022 (Dec) | Not disclosed |
3 years
Jasbir Seehra, Ph.D.President and Chief Executive Officer
| FY2025 (Dec) | Not disclosed | ||||||
| FY2024 (Dec) | |||||||
| FY2023 (Dec) | |||||||
| FY2022 (Dec) | Not disclosed | ||||||
| FY2021 (Dec) | Not disclosed |
5 years
Keith RegnanteChief Financial Officer
| FY2025 (Dec) | Not disclosed | ||||||
| FY2024 (Dec) | |||||||
| FY2023 (Dec) | |||||||
| FY2021 (Dec) | Not disclosed |
4 years
Esther Cho, Esq.Chief Legal Officer
| FY2025 (Dec) |
1 year
CEO pay against the pay peers
In FY2025 (Dec), the median CEO pay of the 7 peers with pay on file was $9.5M. The CEO of Keros Therapeutics was paid $2.5M, 73% below the median.
- 1Scholar Rock Holding
- 2Protagonist Therapeutics
- 3Disc Medicine
- 4IDEAYA Biosciences
- 5Celldex Therapeutics
- 6Kura Oncology
- 7Relay Therapeutics
- 8Keros TherapeuticsThis company
- 9Akero Therapeutics, Inc.Not disclosed
- 10Arcturus Therapeutics HoldingsNot disclosed
- 11Crinetics Pharmaceuticals, Inc.Not disclosed
- 12GeronNot disclosed
- 13Iovance BiotherapeuticsNot disclosed
- 14KalVista Pharmaceuticals, Inc.Not disclosed
- 15Longboard Pharmaceuticals, Inc.Not disclosed
- 16Pliant Therapeutics, Inc.Not disclosed
- 17Replimune Group, Inc.Not disclosed
- 18Rocket Pharmaceuticals, Inc.Not disclosed
- 19SpringWorks Therapeutics, Inc.Not disclosed
- 20Syndax PharmaceuticalsNot disclosed
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.